Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Caio M Rocha Lima, Alberto A Chiappori

Abstract

Despite the high response rates to chemotherapy, small-cell lung cancer (SCLC) is among the most lethal malignancies. Long-term survival is anecdotal for patients with extensive disease; 5-years survival is < or =5% for those with limited disease. All patients with extensive disease and most patients with limited disease will experience disease progression and become candidates for second-line therapy. Although a number of agents have demonstrated antitumor activity in relapsed SCLC, including paclitaxel, docetaxel, etoposide, cisplatin, and carboplatin, topotecan is the only single agent currently approved in the United States for the treatment of recurrent disease. Topotecan is a novel topoisomerase I inhibitor with established antitumor activity in recurrent SCLC and has a predictable, noncumulative toxicity profile. Furthermore, topotecan has been shown to provide symptom improvement in this predominantly palliative setting. Evidence also suggests that topotecan readily penetrates the blood-brain barrier and might be active in the relatively large subset of SCLC patients who experience brain metastases. This article reviews the clinical utility of topotecan in recurrent SCLC, including its efficacy, tolerability, and qualit...Continue Reading

References

Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MasudaM Takada
Apr 1, 1989·British Journal of Cancer·S G SpiroD Eraut
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·L H Einhorn
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U LassenH H Hansen
Jun 16, 2000·Radiologic Clinics of North America·R A Smith, T J Glynn
Sep 15, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·S AgelakiA Raptis
Sep 29, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·W Schuette
Jan 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K GrüschowR Fietkau
Mar 21, 2002·Clinics in Chest Medicine·Bruce E Johnson
Jun 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Aug 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A KorfelE Thiel
Sep 18, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chikako KiyoharaJulian M Hopkin

❮ Previous
Next ❯

Citations

May 17, 2005·Cancer Chemotherapy and Pharmacology·Eva L LundPaul E G Kristjansen
Jan 27, 2007·Current Oncology Reports·Cecilia MacCallum, Heidi H Gillenwater
Nov 13, 2004·Oncology·Annette N Y PoonTony S K Mok
Apr 28, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Bernard LebeauMichel Febvre
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Paul J HeskethDavid R Gandara
Mar 18, 2008·Journal of the American Academy of Dermatology·Noushin HeidarySusan Burgin
Aug 8, 2007·International Journal of Cancer. Journal International Du Cancer·Dean A FennellJustin Stebbing
Apr 26, 2006·Respirology : Official Journal of the Asian Pacific Society of Respirology·Samantha Cooper, Stephen G Spiro
May 19, 2011·The Journal of Pharmacy and Pharmacology·ChunLei LiPing Wang
Apr 26, 2005·Lancet Neurology·Evert C A KaalCharles J Vecht
May 2, 2014·The Korean Journal of Thoracic and Cardiovascular Surgery·Andras Szasz
Aug 9, 2020·Frontiers in Oncology·Andreas SaltosAlberto Chiappori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Marcello Tiseo, Andrea Ardizzoni
© 2022 Meta ULC. All rights reserved